Astellas Pharma said today that, effective Sept. 1, it will let 340B hospitals without an in-house pharmacy pick just one contract pharmacy to furnish Astellas' prostate cancer treatment Xtandi to patients. AstraZeneca, meanwhile, said 340B providers must start using vendor 340B ESP to designate their single-allowed contract pharmacy for certain Astra products.

News Alert

UPDATED: Astellas and AstraZeneca Make 340B Contract Pharmacy Moves

In News Alert, Pharma IndustryJuly 3, 20232133 Views

Rich Daly

Drug manufacturers Astellas and AstraZeneca announced today separate contract pharmacy policies for 340B providers that will go into effect in [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

News Alert

UPDATED: Astellas and AstraZeneca Make 340B Contract Pharmacy Moves

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Rich Daly

News Alert

UPDATED: Astellas and AstraZeneca Make 340B Contract Pharmacy Moves

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Rich Daly

Site Footer